louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06789146: Comparison of the Postoperative Analgesic Effects of SPSIPB and TPB in Mastectomy Operations
Official title: Comparison of the Postoperative Analgesic Effects of Serratus Posterior Superior Intercostal Plane Block and Thoracic Paravertebral Block in Mastectomy Operations
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Mastectomy
Peripheral Nerve Block
Pain Management
Keywords: Mastectomy
Serratus Posterior Superior Intercostal Plane Block
Thoracic Paravertebral Block
Lead sponsor: Ankara Etlik City Hospital
Sponsor class: OTHER_GOV
First posted: 2025-01-23
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Breast cancer is the most common malignancy in women, and surgery is one of the cornerstone treatments for breast cancer. Postoperative pain can significantly reduce patients' quality of life and acute pain may even trigger chronic pain syndrome.

Nerve blocks reduces opioid consumption in the postoperative period by providing better pain control and therefore has advantages such as fewer side effects and less risk of pulmonary and cardiac complications.

In this study; it was aimed to compare the analgesic effectiveness of serratus posterior superior intercostal plane block and thoracic paravertebral block in the postoperative period in patients who underwent mastectomy.


Eligibility criteria: Inclusion Criteria:

* Patients aged 18-80 years
* American Society of Anesthesiologists (ASA) score I-II-III
* Body Mass Index (BMI) between 18-30 kg/m2

Exclusion Criteria:

* Patients under 18 and over 80 years of age
* ASA score IV and above
* Patients with a history of bleeding diathesis
* BMI below 18 or above 30 kg/m2

Primary outcomes:
measure: Pain Scores
timeFrame: On the operation day
Secondary outcomes:
measure: Intraoperative opioid consumption
timeFrame: Intraoperative period
measure: Postoperative Tramadol Consumption
timeFrame: On the operation day
Other outcomes:
Locations:
city: Yenimahalle
country: Turkey
facility: Ankara Etlik City Hospital
state: Ankara
Study officials:
References:
Clinical trial NCT04862546: Laser Acupuncture Versus Tap Water Iontophoresis on Hyperhidrosis
Official title: Effect of Acupuncture Points Laser Versus Tap Water Iontophoresis on Hyperhidrosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hyperhidrosis
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2021-04-28
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 22
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the purpose of the present study is to assess the effect of laser acupoints on subjects with hyperhidrosis in comparison to tap water iontophoresis

Detailed description: The study will be randomized control trial pre and post-experimental design. Anonymity and confidentiality of all procedures will be assured in compliance with relevant laws and institutional guidelines. All patients will sign two copies of a consent form before the beginning of data collection. Subjects will be recruited using publicly distributed posters and by online social media, subjects their hyperhidrosis examined by Hyperhidrosis Disease Severity Scale, Perceived Stress Scale. Recruited subjects will be randomly assigned to Laser Acupoint or Tap water iontophoresis groups. The participants and assessor will be blinded for the study hypothesis.

Eligibility criteria: Inclusion Criteria:

* volunteer subjects from MIT physical therapy students complained from hyperhidrosis examined by Hyperhidrosis Disease Severity Scale, Perceived Stress Scale.

Exclusion Criteria:

* Subjects will be excluded if they had musculoskeletal diseases and visceral disorders or had any operations or recent injury

Primary outcomes:
measure: Hyperhidrosis Disease Severity Scale
timeFrame: Change between baseline and 2 weeks of treatment measures
Secondary outcomes:
Other outcomes:
Locations:
city: Kafr Ash Shaykh
country: Egypt
facility: Kafrelshaikh University
Study officials:
References:
Clinical trial NCT03736746: Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals
Official title: Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Other Cancer
Keywords: Other Cancer
Lead sponsor: Dana-Farber Cancer Institute
Sponsor class: OTHER
Collaborators: name: Sigma Theta Tau International Honor Society of Nursing
First posted: 2018-11-09
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This research study is evaluating the acceptability and feasibility of using a cognitive behavioral intervention called Motivational Interviewing to help persons with pain from cancer set goals for managing that pain.

Detailed description: This study is being conducted to evaluate a new way that clinicians can help identify the goals that cancer participants have for managing their pain. This new method uses discussion between a patient and a clinician, in this case a registered nurse, during which one or more goals may be set. At this time, there are no tested methods that clinicians can use for helping patients set these kinds of goals.

Eligibility criteria: Inclusion Criteria:

* At least 18-years of age
* Has an appointment with DFCI ambulatory palliative care service for cancer-related pain
* Can speak English

Exclusion Criteria:

-Diagnosis of delirium or other cognitive impairment

Primary outcomes:
measure: Feasibility of Motivational Interviewing intervention
timeFrame: 1 year
Secondary outcomes:
measure: Motivational Interviewing intervention usage rate
timeFrame: 1 year
measure: Participant intervention acceptability
timeFrame: 1 year
measure: Attitudinal barriers to pain
timeFrame: 1 year
measure: Pain Self-Efficacy
timeFrame: 1 year
measure: Observed engagement in goals-setting
timeFrame: 1 year
measure: Motivational Interviewing intervention fidelity
timeFrame: 1 year
Other outcomes:
Locations:
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Olga Ehrlich, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00090246: 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
Official title: A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of 2 Doses of Aprepitant for the Prevention of Postoperative Nausea and Vomiting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Postoperative Nausea and Vomiting
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2004-08-27
Enrollment: 922
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay.

Detailed description: The duration of treatment is 4 weeks.

Eligibility criteria: Inclusion Criteria:

* Patient is at least 18 years of age.
* Patient is scheduled to undergo open abdominal surgery requiring overnight hospital stay (24-hour hospital stay after end of surgery).
* Patient is scheduled to receive general anesthesia.
* Patient is scheduled to receive postoperative opioids.

Primary outcomes:
measure: Prevention of PONV in the 24 hours following end of surgery; Tolerability
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Diemunsch P, Gan TJ, Philip BK, Girao MJ, Eberhart L, Irwin MG, Pueyo J, Chelly JE, Carides AD, Reiss T, Evans JK, Lawson FC; Aprepitant-PONV Protocol 091 International Study Group. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth. 2007 Aug;99(2):202-11. doi: 10.1093/bja/aem133. Epub 2007 May 30.
citation: Diemunsch P, Apfel C, Gan TJ, Candiotti K, Philip BK, Chelly J, Carides AD, Evans JK, Ho TW, Reiss T. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant. Curr Med Res Opin. 2007 Oct;23(10):2559-65. doi: 10.1185/030079907X233115.
citation: Goveia MG, DiNubile MJ, Dallas MJ, Heaton PM, Kuter BJ; REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr Infect Dis J. 2008 Jul;27(7):656-8. doi: 10.1097/INF.0b013e318168d29e.
Clinical trial NCT01470846: Postoperative Analgesia in Abdominal Surgery: a Medico-economic Study
Official title: Epidural Analgesia vs. Morphine Patient-controlled Analgesia in Abdominal Surgery Under Laparotomy : a Medico-economic Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Extended Ileal Resection Under Laparotomy
Total Proctocolectomy Under Laparotomy
Colectomy Left/Right/Total Under Laparotomy
Rectosigmoidal Resection Under Laparotomy
Anterior Resection of Rectum Under Laparotomy
Abdomino-perineal Amputation Under Laparotomy
Keywords: epidural analgesia
morphin analgesia
laparotomy
Lead sponsor: University Hospital, Limoges
Sponsor class: OTHER
First posted: 2011-11-11
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background : Epidural anaesthesia is associated in abdominal surgery with reduced pain and postoperative respiratory complications together with quicker recovery of bowel function. Currently, no studies have been able to prove its ability to reduce length of stay in intensive care and high-dependency units.

Purpose : The aim of this study is to demonstrate that epidural anaesthesia reduces length of stay in intensive care unit after abdominal surgery under laparotomy.

Detailed description: There are currently two methods of analgesia in postoperative abdominal surgery : patient-controlled analgesia (PCA) with opioids and epidural analgesia.

No international recommendations regarding the use of either of these techniques have yet been written. Epidural analgesia is superior to intravenous morphine, including during mobilization and coughing. It also reduces respiratory complications and optimizes postoperative rehabilitation. Nevertheless, mortality is not improved with this technique. Few publications exist on the optimization of the duration of hospitalization in the intensive care unit.

Eligibility criteria: Inclusion Criteria:

* Surgery scheduled under laparotomy
* Extended ileal resection
* Total proctocolectomy
* Colectomy left/right/total
* Rectosigmoidal resection
* Anterior resection of rectum
* Abdomino-perineal amputation
* Adult patient
* Written consent obtained
* Planned hospitalization in the intensive care unit
* Patient affiliated to social security

Exclusion Criteria:

* Patients inapt to give consent
* Emergency surgery
* Contraindication to epidural analgesia
* Contraindication to levobupivacaïne, morphine or sufentanil
* Dementia
* Participation in another research protocol
* Pregnancy or breastfeeding

Primary outcomes:
measure: Theoretical duration of hospitalization in intensive care unit.
timeFrame: 5 days
Secondary outcomes:
measure: Total duration of hospitalization.
timeFrame: 9 days
Other outcomes:
Locations:
city: Limoges
country: France
facility: CHU de Limoges - Service d'anesthésie-réanimation
Study officials:
affiliation: Limoges UH
name: Nathalie NATHAN-DENIZOT, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03197246: Intravascular ECG During Insertion of Peripheral Inserted Central-venous Catheters: Replacement for Chest X-ray?
Official title: May Intravascular Electrocardiography (IVECG) During Insertion of Peripheral Inserted Central-venous Catheters (PICC-line) Replace Chest X-ray?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Catheterization, Peripheral
Electrocardiography
Keywords: PICC line
ECG
chest x-ray
IVECG
ICECG
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: Sykehuset Innlandet HF
First posted: 2017-06-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: RCT, two groups
Primary purpose: OTHER

Brief summary: This study will provide further knowledge concerning the use of electrocardiography (ECG) signals for verification of peripherally inserted central catheter (PICC) tip placement. Furthermore, it will be investigating whether use of Intravascular ECG (IVECG) for this verification is just as good as or even better than the current standard method with chest X-ray. This can help promote a method that involves less radiation and increased safety for patients, while at the same time saving resources. If use of ECG signals from the PICC tip is an equally exact method for verification of correct PICC tip placement as chest X-ray verification, the IVECG could replace chest X-ray control.


Eligibility criteria: Inclusion Criteria:

* In need for PICC
* \>18 years old
* Competent to give consent

Exclusion Criteria:

* Not visible p-wave on surface ECG (electrocardiograph)
* Patients with known Atrial fibrillation or atrial flutter
* Implanted pacemaker (PM) and/or implanted Implantable Cardioverter Defibrillator (ICD)
* Not signed written informed consent

Primary outcomes:
measure: PICC-tip placement examined by chest X-ray
timeFrame: 45 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Lillehammer
country: Norway
facility: Innlandet Hospital Trust Lillehammer
state: Oppland
Study officials:
affiliation: Sykehuset Innlandet HF
name: Baard Olav Jensen, MD,PhD
role: STUDY_CHAIR
affiliation: NTNU, MH, Masterutdanning
name: Jon Magnussen, prof
role: STUDY_DIRECTOR
References:
Clinical trial NCT03223246: Medication Education for Dosing Safety
Official title: Medication Education for Dosing Safety
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Fever
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2017-07-21
Enrollment: 149
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Acetaminophen and ibuprofen are two of the most commonly used medication products among children \<12 years old, and these medications are frequently prescribed for patients leaving the emergency department (ED), but previous studies have shown that parents often leave the ED unsure of how to safely dose these medications at home. This study will be a randomized controlled trial of a brief medication safety intervention, and examining parental knowledge and implementation of appropriate weight-based dosing.


Eligibility criteria: Inclusion Criteria:

* parents of children between ages of 90 days to 11.9 years
* being discharged with a plan for use of liquid acetaminophen (any age) or ibuprofen (limited to those \>6 months old). The clinical team will determine planned medication use.
* parental fluency in English or Spanish
* ability to be reached by telephone over the next 7 days
* planned discharge home.

Exclusion Criteria:

* presence of a complex chronic condition in the child
* planned use of a non-standard weight-based medication dose.
* Families will also be excluded if the adult with the child is not a parent or legal guardian.

Primary outcomes:
measure: Number of Participants Reporting Safe Dosing at 48-72 Hours
timeFrame: 48-72 hours
Secondary outcomes:
measure: Number of Participants Reporting Persistence of Safe Dosing at 5-7 Days
timeFrame: 5-7 days
measure: Number of Participants Reporting Contact With Other Providers at 48-72 Hours
timeFrame: 48-72 hours
measure: Number of Participants Reporting Contact With Other Providers at 5-7 Days
timeFrame: 5-7 days
Other outcomes:
measure: Number of Participants Reporting Each Direction of Dosing Error at 48-72 Hours
timeFrame: 48-72 hours
measure: Number of Participants Reporting Each Direction of Dosing Error at 5-7 Days
timeFrame: 5-7 days
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: MGH
name: Margaret Samuels-Kalow, MD MSHP
role: PRINCIPAL_INVESTIGATOR
References:
citation: Naureckas Li C, Camargo CA Jr, Faridi M, Espinola JA, Hayes BD, Porter S, Cohen A, Samuels-Kalow M. Medication Education for Dosing Safety: A Randomized Controlled Trial. Ann Emerg Med. 2020 Nov;76(5):637-645. doi: 10.1016/j.annemergmed.2020.07.007. Epub 2020 Aug 15.
Clinical trial NCT00374946: A Clinical Evaluation of Wear Couples in THA
Official title: A Randomised Controlled Clinical Study Ofbearing Surfaces in Four Hybrid Prosthesis - Results After 10 Years
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Articular Bearing Surface Wear of Prosthetic Joint
Wear of Articular Bearing Surface of Prosthetic Joint
Prosthesis Survival
Lead sponsor: Frederiksberg University Hospital
Sponsor class: OTHER
First posted: 2006-09-12
Enrollment: 392
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients referred to the orthopedic department in the inclusion period fulfilling the inclusion criteria and not having any of the exclusion criteria

Brief summary: Clinical evaluation of 4 different bearings in THA. Primary parameter being prosthetic survival data.


Eligibility criteria: Inclusion Criteria:

* \>18 Willing to participate informed consents indication for THA

Exclusion Criteria:

* \<18 other diseases in the lower extremities than the actual disorder of the hip

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Frederiksberg UH
name: Arne Borgwardt, md
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06913946: Validity of MNI and Its Relationship With HEI-2015
Official title: Validity of the 'My Nutrition Index' (MNI) and Its Relationship With the Healthy Eating Index-2015 in the Turkish Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy People
Keywords: My Nutrition Index, Healthy Eating Index, Dietary Assessment
Lead sponsor: Ankara Yildirim Beyazıt University
Sponsor class: OTHER
First posted: 2025-04-06
Enrollment: 498
Sex: ALL
Minimum age (years): 19
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Community sample in Türkiye

Brief summary: This study assessed the validity of the "My Nutrition Index" (MNI) and its relationship with the Healthy Eating Index-2015 (HEI-2015) in the Turkish population. A cross-sectional study of 498 participants aged 19-64 years was conducted, collecting demographic, anthropometric, and three-day food consumption data to calculate both indices. Pearson's correlation was used for analysis.

Detailed description: Introduction: Healthy eating is a crucial concept encompassing biochemical, physical, and psychosocial domains, and various nutritional indices and scales have been developed to assess the healthfulness of individuals' diets.

Objective: This study aimed to evaluate the validity of the "My Nutrition Index" (MNI) and examine its relationship with the Healthy Eating Index-2015 (HEI-2015) in the Turkish population.

Methods: This cross-sectional study included 498 participants aged 19-64 years. Demographic and anthropometric data were collected, and three-day food consumption records were obtained to calculate both the My Nutrition Index and the Healthy Eating Index-2015. Participants' nutritional data were analyzed, and the relationship between the two indices was examined using Pearson's correlation test. Data analysis was performed using the IBM SPSS Statistics 26 software package.

Eligibility criteria: Inclusion Criteria:

-Individuals aged 19-64 years

Exclusion Criteria:

* Individuals with physician-diagnosed psychological disorders.
* Individuals who regularly used medication or vitamin supplements.
* Individuals with alcohol or substance addiction.
* Pregnant or nursing women.

Primary outcomes:
measure: My Nutrition Index
timeFrame: Baseline
measure: Healthy Eating Index-2015
timeFrame: Baseline
Secondary outcomes:
measure: International Physical Activity Questionnaire
timeFrame: Baseline
measure: Sociodemographic characteristics
timeFrame: Baseline
measure: Body Mass Index (BMI)
timeFrame: Baseline
measure: Body weight
timeFrame: Baseline
measure: Height
timeFrame: Baseline
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara Yıldırım Beyazıt University
Study officials:
References: